ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

¹­ÐγæÐÔ·ÎÑ׵IJ¡ÀíлúÖÆ¼°ÖÎÁÆÐÂÕ½ÂÔ

¸å¼þȪԴ£º£ºÉúÃü¿ÆÑ§Ñ§Ôº ±à¼­£º£ºÌ¸Ï£ ¡¢¡¢Íõ¶¬Ã· ÉóºË£º£ºÖª×ã ÔĶÁÁ¿£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±ÕÅÒÕÁÖ£©¸ÕµØ¹­Ðγ棨Toxoplasma gondii£¬£¬£¬¼ò³Æ¹­Ðγ棩ÊÇÒ»ÖÖÑÏ¿áµÄϸ°ûÄÚ¼ÄÉúÔ­³æ£¬£¬£¬Ô¤¼ÆÈ«ÇòÔ¼ÓÐ30%-50%Éú³ÝÊÜÆäѬȾ£¬£¬£¬¶øÓɹ­ÐγæÑ¬È¾ËùÒýÆðµÄ¹­Ðγ没ÒѳÉÎªÖØ´óµÄ¹«¹²ÎÀÉúÎÊÌâÖ®Ò»¡£¡£¡£¹­ÐγæÑ¬È¾¿Éµ¼Ö¶àÆ÷¹ÙËðÉË£¬£¬£¬ÆäÖзβ¿Êǹ­ÐγæÑ¬È¾Ê±×î³£ÀÛ¼°µÄÆ÷¹ÙÖ®Ò»¡£¡£¡£·Î¹­Ðγ没»¼ÕßÔÚÓ×¶ù ¡¢¡¢ºÏ²¢·Î½áºË¼°ÃâÒßÁ¦µÍϵÄÍíÄêÈËȺÌåÖÐÒ×Ðγɼ± ¡¢¡¢ÂýÐÔѬȾ£¬£¬£¬ÔÚÆ÷¹ÙÒÆÖ² ¡¢¡¢ºÏ²¢°¬×̲¡µÄ»¼ÕßÖпÉÔì³ÉÖÂÃüÐÔʱ»úÐÔѬȾ£¬£¬£¬ÌåÏÖΪ¹­ÐγæÐÔ·ÎÑס£¡£¡£¹­ÐγæÐÔ·ÎÑ×ÁÙ´²ÌåÏÖÑÏÖØ£¬£¬£¬ÇÒ²¡³Ì¿ªÕ¹¿ì£¬£¬£¬²¡ËÀÂʸß¡£¡£¡£ngµç×ÓÓÎÏ·ÉúÃü¿ÆÑ§Ñ§ÔºÂ×ÕÕÈÙ½ÌÊÚÔøÓëÓ¢¹úѧÕßÏàÖú£¬£¬£¬·¢Ã÷ÔÚ¼ì²éµÄ72¸öÓ¢¹úÂü³¹Ë¹ÌØÒ½ÔºÊÕÖεķΰ©»¼ÕßÖУ¬£¬£¬¹­ÐγæÑ¬È¾ÂÊ´ï100%£¬£¬£¬ÌáÐÑÁ˹­Ðγ没ÖÎÁƵÄÖ÷ÒªÐÔ¡£¡£¡£ÏÖÔÚ£¬£¬£¬¹­Ðγ没µÄÁÙ´²ÖÎÁÆÕ½ÂÔÖ÷ҪΪÒÒ°·à×à¤Óë»Ç°·à×à¤ÁªÓ㬣¬£¬¿Éͨ¹ýÒÖÖÆ¹­ÐγæDNAºÏ³ÉÀ´×è¶ÏÆä¸´ÖÆ¡£¡£¡£È»¶ø£¬£¬£¬´ËÀàÁÆ·¨ÆðЧʱ¼ä½Ï³¤£¬£¬£¬ÇÒÎÞ·¨ÓÐÓûº½â¹­ÐγæÑ¬È¾ËùÒýÆðµÄ·ÎÑ×Ö¢×´¡£¡£¡£Òò´Ë£¬£¬£¬ÈÔÐèÉîÈë̽ÌÖ¹­ÐγæÐÔ·ÎÑ×±¬·¢¿ªÕ¹µÄ·Ö×Ó»úÀí£¬£¬£¬ÍÚ¾òеĿ¹Ñ×ÁÆ·¨¡£¡£¡£

ÈÕǰ£¬£¬£¬ngµç×ÓÓÎÏ·ÉúÃü¿ÆÑ§Ñ§ÔºÖÜÎÄÁ¼½ÌÊÚÍŶÓÓëÂ×ÕÕÈÙ½ÌÊÚÏàÖúÔÚ¹­ÐγæÐÔ·ÎÑ×·¢²¡»úÖÆ¼°ÖÎÁÆÕ½ÂÔ·½ÃæÈ¡µÃеÄÖ÷ҪϣÍû¡£¡£¡£¸ÃÍŶÓʹÓõçÐÄÀíѧ ¡¢¡¢·Ö×ÓÉúÎïѧ ¡¢¡¢Ï¸°ûÉúÎïѧµÈʵÑéÊÖÒÕ£¬£¬£¬ÉîÈëÆÊÎöÁ˹­ÐγæÑ¬È¾Í¨¹ý½éµ¼Ï¸°ûÄÚÂÈÀë×ÓÒì³£»£»£»ýÀÛÒýÆð·Î²¿Ñ×֢ǨÑÓ²»ÓúµÄ²¡ÀíлúÖÆ£¬£¬£¬²¢½øÒ»²½É¸Ñ¡³öÓÐÓûº½â¹­ÐγæÐÔ·ÎÑ×µÄ×ÔÈ»²úÆ·¡£¡£¡£

¸ÃÑо¿ÒÔÆøµÀÉÏÆ¤Ï¸°ûÖêÓëÔ­´ú×÷ÓýµÄÈËÆøµÀÉÏÆ¤Ï¸°ûΪÌåÍâÑо¿Ä£×Ó£¬£¬£¬Á¬Ïµ¹­ÐγæÑ¬È¾µÄÔÚÌåСÊó·ÎÑ×Ä£×Ó£¬£¬£¬·¢Ã÷¹­ÐγæÔÚÇÖϮϸ°ûµÄÀú³ÌÖУ¬£¬£¬¿Éͨ¹ýÉøÍ¸¶àÖÖ°ëë×°±ËáÂѰ×ø£¨cysteine proteases£©ÒýÆð±í´ïÓÚÆøµÀÉÏÆ¤Ï¸°ûĤÉϵÄÂÈÀë×ÓͨµÀ¡ª¡ªÄÒÐÔÏËά»¯¿çĤ´«µ¼µ÷ÀíÒò×Ó£¨cystic fibrosis transmembrane conductance regulator£¬£¬£¬CFTR£©½µ½â£¬£¬£¬½ø¶øÒÖÖÆ¿çÉÏÆ¤ÂÈÀë×ÓÉøÍ¸²¢½éµ¼Ï¸°ûÄÚÂÈÀë×ÓÒì³£»£»£»ýÀÛ¡£¡£¡£ÖµµÃ×¢ÖØµÄÊÇ£¬£¬£¬¹­ÐγæÑ¬È¾»¹¿ÉÒÔͨ¹ý¼¤»îÂÈÀë×ÓÃô¸ÐµÄѪÇåÌÇÆ¤Öʼ¤Ëص÷Àí¼¤Ã¸1£¨serum glucocorticoid regulated kinase 1£¬£¬£¬SGK1£©ÐźÅͨ·£¬£¬£¬´¥·¢NF-¦ÊBÒÀÀµµÄÁ×Ëá¶þõ¥Ã¸4£¨phosphodiesterase 4£¬£¬£¬PDE4£©-cAMP-CFTR-ÂÈÀë×Ó-SGK1Õý·´À¡Ñ­»·£¬£¬£¬µ¼Ö·β¿Ñ×֢ǨÑÓ²»Óú¡£¡£¡£±ðµÄ£¬£¬£¬¸ÃÑо¿»¹½øÒ»²½Ì½Ë÷ÁË¿¹¹­ÐγæÐÔ·ÎÑ×µÄÐÂÐÍÖÎÁÆÕ½ÂÔ£¬£¬£¬·¢Ã÷×ÔÈ»²úÆ·´óËâËØ¿Éͨ¹ý¼¤»îCFTRÒÖÖÆÏ¸°ûÄÚÂÈÀë×Ó»ýÀÛÓë³ÖÐøÐÔÑ×Ö¢·´Ó³¡£¡£¡£ÔÚÌ嶯ÎïʵÑéЧ¹ûÒ²Åú×¢£¬£¬£¬Îí»¯ÎüÈë´óËâËØ¿ÉÓÐÓûº½â¹­ÐγæÑ¬È¾Ä£×ÓСÊóµÄ·ÎÑ×Ö¢×´£¬£¬£¬ÌáÐÑÁË´óËâËØÓÃÓÚÖÎÁƹ­ÐγæÐÔ·ÎÑ×µÄÓÅÒìÓ¦ÓÃÔ¶¾°¡£¡£¡£


7D34CDC73C3F46A894F4F6FAAC2_26E3F02C_A85B

ͼ1 ¹­ÐγæÐÔ·ÎÑ×·¢²¡¼°´óËâËØ¿¹Ñ×ÖÎÁƵĻúÖÆÊ¾Òâͼ


ÔÚ2015Äê½ÒÏþÔÚÃÀ¹ú¹ú¼Ò¿ÆÑ§ÔºÔº¿¯PNASµÄÂÛÎÄÖУ¬£¬£¬ÖÜÎÄÁ¼½ÌÊÚÓëÂ×ÕÕÈÙ½ÌÊÚÏàÖú£¬£¬£¬·¢Ã÷¹­ÐγæÑ¬È¾¿ÉÒýÆðÆøµÀÉÏÆ¤Ï¸°ûÂÈÀë×ÓתÔËÊÜ×è¡£¡£¡£ÔÚ2018Äê½ÒÏþÓÚ¹ú¼Êð¤Ä¤ÃâÒßѧ»á¹Ù·½ÆÚ¿¯Mucosal ImmunolµÄÂÛÎÄÖУ¬£¬£¬ÖÜÎÄÁ¼½ÌÊÚ¼°ÍŶÓÖ÷¸ÉÕÅÒÕÁÖÌØÆ¸¸±Ñо¿Ô±Õ¹ÏÖÁËϸ°ûÄÚÂÈÀë×ÓÐźÅͨ·ÔÚϸ¾úѬȾËùÖÂÆøµÀÑ×Ö¢ÖеÄ×÷ÓûúÖÆ¡£¡£¡£ÔÚ±¾Ñо¿ÖУ¬£¬£¬¸ÃÑо¿ÍŶӽøÒ»²½Ö¤ÊµÎúϸ°ûÄÚÂÈÀë×ÓÐźÅͨ·ÔÚ¹­ÐγæÐÔ·ÎÑ×·¢²¡ÖÐʩչÁËÖ÷Òª×÷Ó㬣¬£¬²¢É¸Ñ¡³ö°ÐÏòÒÖÖÆ¸Ãͨ·µÄ×ÔÈ»²úÆ·£¬£¬£¬¿ÉΪ¹­ÐγæÐÔ·ÎÑ×µÄÐÂÒ©Ñз¢ÊÂÇéÌṩÖ÷ÒªµÄ¿ÆÑ§ÒÀ¾Ý¡£¡£¡£

¸ÃÑо¿Ð§¹ûÒÔ¡°Toxoplasma gondii infection triggers ongoing inflammation mediated by increased intracellular Cl? concentration in airway epithelium¡±ÎªÌ⣬£¬£¬ÓÚ2023Äê1Ô½ÒÏþÔÚÓ¢¹úѬȾ²¡Ð­»á£¨British Infection Association£¬£¬£¬BIA£©¹Ù·½ÆÚ¿¯Journal of Infection¡£¡£¡£ngµç×ÓÓÎÏ·ÉúÃü¿ÆÑ§Ñ§ÔºÎªµÚÒ»×÷Õßµ¥Î»¡£¡£¡£¸ÃÊÂÇé»ñµÃÁ˹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÇàÄêÏîÄ¿ ¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ð²©Ê¿Æô¶¯ÏîÄ¿µÈ»ù½ð×ÊÖú¡£¡£¡£

ÂÛÎÄÁ´½Ó£º£ºhttps://www.sciencedirect.com/science/article/pii/S0163445322006351

¡¾ÍøÕ¾µØÍ¼¡¿